1. Trana Discovery, Inc.Developing tools to find new treatments for serious infectious diseases Staphylococcusaureus HTS Assay July 2011

2. Introducing Trana Discovery An anti-infective drug discovery technology company Who we are: Enable organizations to find novel classes of drugs for the treatment of serious viral, bacterial and fungal infectious diseases What we do: Technology identifies compounds that work through a unique mechanism of action: the target pathogen’s ability to use organism-specific transfer RNA (tRNA) in protein synthesis How it works: Applies to human, animal and plant pathogens Where it works: 2

3. Management Team Over 300 combined years of research, discovery, clinical, financial, accounting, sales, product development, and marketing experience Steve Peterson, CEO Winnell Newman, Co-founder Dick Guenther, CTO Mike Gallucci, Sr. VP, Finance & CFO Michael Ossi, MD, CSO Sam Yenne, PhD, VP, Chief Development Officer Chris Ellis, Director, Bioinformatics tRNA Database Dan Mitchell, PharmD, VP Dan Sternbach, PhD, Director, Medicinal Chemistry Ed Gallagher, VP, Intellectual Prop. Karl von Gunten, VP, Communications Leigh Ann Gallucci, VP, Fin. Reporting & Acct. Frank Johnson, VP, Sales & Marketing AndrzejMalkiewicz, Scientific Research Consultant 3

4. Intellectual Property 16 patents issued, licensed and pending Extensive patent surveys confirm freedom to operate Licensed production of probes from Technical University Filed US and International patents for discovery and diagnostic applications 4

5. Market Needs Desperate Need for New Classes of Anti-infectives Staphylococcus aureus A major health concern MRSA resistant to most antibiotics 5% of all hospital and nursing home patients are infected with MRSA New Drug Pipeline 1988 - 1992: average of three new antibiotic approvals each year Since 2003: average one new approval a year 5

6. Trana S. aureus Assay Components Ribosome complex programmed with a short oligomer representing mRNA Codon for fMet at the P site Codon for a S. aureus specific tRNA at the A site Full length fMet tRNA used to stabilize the complex prior to the addition of an RNA mimic for tRNAArgASL Cartoon of protein synthesis. (Source: Wikimedia Commons) 6 ASL Arg

7. Trana S.aureus HTS Assay Uses a fluorescein-labeled oligonucleotide mimic of the ASL loop of tRNAArg with a programmed ribosome Identifies compounds that inhibit the use of tRNAArg that is specific to S. aureus and which is required for protein synthesis Assay optimized for high-throughput screening Development funded through small business research loan from NCBC 7

8. Assay Validation 8 60,000 compound library screening identified 283 compounds 89 confirmed as biochemically active in dose response curve study 38 selected based on an acceptable IC50 concentration 8 demonstrated activity against 2 or more strains of S. aureus in a bacterial assay

9. Value Proposition Low risk, low cost means for identification of drug candidates High certainty of effectiveness Licensing opportunities for exclusive rights to new drug classes 9

10. Licensing Models 1. Individual Company License Use rights of assay with milestone and royalty payments based on development and commercial success 2. Exclusive Option License Exclusivity offered to one company - currently available Milestone and royalty payments scheduled downstream as drugs progress to market Applies to discovery product areas (both options include rights to patented identified compounds, additionally first refusal option available) 10

11. Please Feel Free to Contact Steve Peterson, CEO stevepeterson@tranadiscovery.com Sam Yenne, PhD, VP, Chief Development Officer samyenne@tranadiscovery.com Frank Johnson, VP, Sales & Marketing frankjohnson@tranadiscovery.com 919-303-4948 www.tranadiscovery.com 11